Clinical trials - Cancer Research SA

Filter By

ZN C3 002

Phase 1b

Open and recruiting

Ovarian – Platinum Resistant

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Read more: Ovarian – Platinum Resistant
TROPION LUNG U303

Phase 3

Open and recruiting

Lung Cancer PD-L1 <50% 1st line met

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Read more: Lung Cancer PD-L1 <50% 1st line met
OPERA OP-1250-301

Phase 3

Open and recruiting

Breast ER+/HER2- 2nd line met

This phase 3 clinical study compares the safety and efficacy of OP-1250 to the standard of care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on at least one endocrine therapy in combination with a CDK4/6 inhibitor.
Read more: Breast ER+/HER2- 2nd line met
ONC-392-001

Phase 1

Open and recruiting

Advanced or Metastatic Solid Tumours

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Read more: Advanced or Metastatic Solid Tumours
MK3475-D46. EVOKE 3

Phase 3

Open and recruiting

Lung Cancer PD-L1 ≥50% 1st line met

Read more: Lung Cancer PD-L1 ≥50% 1st line met
LOXO-PIK

Phase 1a, Phase 1b

Open and recruiting

PIK C3A – Advanced or metastatic solid tumours

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly…
Read more: PIK C3A – Advanced or metastatic solid tumours
LIDERA

Phase 3

Breast ER+/Her2- Early Stage

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Read more: Breast ER+/Her2- Early Stage
HER2CLIMB

Phase 3

Open and recruiting

Breast Her2+ 1st line met

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this…
Read more: Breast Her2+ 1st line met
GS-US-592-6238 ASCENT 03

Phase 3

Open and recruiting

Breast TNBC PDL1- 1st line met

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician’s choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell…
Read more: Breast TNBC PDL1- 1st line met